21st Century Cures Act and 42 CFR Part 2

21st Century Cures Act and 42 CFR Part 2: A Comprehensive Guide for CIPP/US Exam Preparation

Introduction

The 21st Century Cures Act and the regulations found in 42 CFR Part 2 represent a critical intersection of health privacy law, substance use disorder (SUD) treatment confidentiality, and the evolving landscape of health information exchange in the United States. For CIPP/US candidates, understanding this topic is essential because it sits at the nexus of federal privacy protections that limit the private sector's collection and use of sensitive health data. This guide will explain what these laws are, why they matter, how they work, and how to approach exam questions on this topic.

What Is the 21st Century Cures Act?

The 21st Century Cures Act (Cures Act) was signed into law in December 2016. It is a broad piece of legislation designed to accelerate medical product development, bring innovations and advances to patients faster, and modernize clinical trials. However, for privacy professionals, its significance lies primarily in its provisions related to health information technology, interoperability, and information blocking.

Key privacy-relevant provisions include:

- Interoperability and Information Blocking: The Cures Act mandates that health information technology (HIT) developers, health information networks, and healthcare providers do not engage in practices that unreasonably restrict the access, exchange, or use of electronic health information (EHI). This is known as the information blocking prohibition.

- Patient Access: The Act emphasizes patients' right to access their own electronic health information without being subjected to unreasonable barriers.

- ONC Health IT Certification Program: The Cures Act directed the Office of the National Coordinator for Health Information Technology (ONC) to update certification criteria to promote interoperability and the secure exchange of health data.

- Impact on 42 CFR Part 2: The Cures Act included provisions that addressed the alignment of substance use disorder treatment records with broader health information exchange frameworks, setting the stage for subsequent regulatory updates to 42 CFR Part 2.

What Is 42 CFR Part 2?

42 CFR Part 2 is a federal regulation that governs the confidentiality of substance use disorder (SUD) patient records. Originally enacted in the 1970s, these regulations were designed to encourage individuals to seek treatment for drug and alcohol abuse without fear that their sensitive treatment information would be disclosed and used against them — for example, in criminal proceedings, employment decisions, or other discriminatory contexts.

Key features of 42 CFR Part 2 include:

- Applicability: 42 CFR Part 2 applies to any program that is federally assisted and that holds itself out as providing, and does provide, substance use disorder diagnosis, treatment, or referral for treatment. Federally assisted includes programs that receive federal funding, are carried out under a federal license, or are conducted by a federal department or agency.

- Consent Requirement: Patient records related to SUD treatment may not be disclosed without the written consent of the patient, except in very limited circumstances. This consent requirement is more restrictive than HIPAA's general provisions for treatment, payment, and healthcare operations (TPO).

- Prohibition on Re-disclosure: When SUD records are disclosed with patient consent, the recipient receives a notice that the information is protected under federal law and cannot be further disclosed without additional patient consent. This prohibition on re-disclosure is a hallmark of 42 CFR Part 2.

- Limited Exceptions: Disclosure without consent is permitted only in narrow circumstances, such as medical emergencies, audits and evaluations, qualified service organization agreements (QSOAs), communications within a program, reporting of suspected child abuse or neglect, court orders (which require a specific judicial process, not just a subpoena), and certain research activities.

- Criminal Penalties: Violations of 42 CFR Part 2 can result in criminal fines, unlike HIPAA which primarily relies on civil penalties enforced by HHS (though HIPAA also has criminal provisions).

Why Is This Topic Important?

Understanding the relationship between the 21st Century Cures Act and 42 CFR Part 2 is important for several reasons:

1. Heightened Protection for Sensitive Data: SUD treatment records receive a higher level of protection than general health information under HIPAA. This reflects a policy judgment that the stigma associated with substance use disorders requires additional safeguards to prevent discrimination and encourage treatment-seeking behavior.

2. Tension Between Interoperability and Privacy: The Cures Act promotes the free flow of health information to improve care coordination and patient outcomes. However, 42 CFR Part 2's strict consent and re-disclosure requirements can create friction with these interoperability goals. Understanding how regulators and legislators have tried to balance these competing interests is essential.

3. Evolving Regulatory Landscape: In recent years, there have been significant regulatory updates to 42 CFR Part 2, partly driven by the Cures Act. The Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 and the Consolidated Appropriations Act of 2023 further amended 42 CFR Part 2 to better align it with HIPAA in certain respects while maintaining core patient consent protections. HHS finalized a rule in 2024 implementing these changes.

4. Private Sector Compliance: Many private sector entities — hospitals, health systems, electronic health record vendors, health information exchanges, insurance companies, and behavioral health providers — must navigate the interplay between HIPAA, 42 CFR Part 2, and the Cures Act. For a CIPP/US candidate, understanding these limits on private sector collection and use of SUD data is directly relevant to the exam.

How Do the 21st Century Cures Act and 42 CFR Part 2 Work Together?

The interplay between these two legal frameworks can be understood through several key dynamics:

1. Information Blocking vs. Part 2 Protections
The Cures Act's information blocking provisions require that healthcare actors not unreasonably interfere with the exchange of electronic health information. However, the information blocking rule recognizes a privacy exception: an actor does not engage in information blocking if it refrains from sharing data in order to comply with applicable privacy laws, including 42 CFR Part 2. In other words, a provider is not engaging in information blocking by refusing to share SUD records when the patient has not provided the required Part 2 consent.

2. Alignment with HIPAA
Historically, 42 CFR Part 2 operated as a separate and more restrictive framework than HIPAA. Recent legislative and regulatory changes — driven in part by the Cures Act and subsequent legislation — have moved toward greater alignment. Key areas of alignment include:

- Allowing disclosure of Part 2 records for treatment, payment, and healthcare operations (TPO) with a single initial consent, rather than requiring consent for each individual disclosure.
- Applying HIPAA's breach notification requirements to Part 2 records.
- Applying HIPAA's enforcement framework, including civil penalties, to Part 2 violations.
- Allowing patients to exercise HIPAA-like rights (such as the right to an accounting of disclosures and the right to request restrictions) with respect to Part 2 records.

3. Maintained Protections
Despite the alignment efforts, 42 CFR Part 2 retains several protections that go beyond HIPAA:

- Use in legal proceedings: Part 2 records still cannot be used in civil, criminal, administrative, or legislative proceedings against the patient without the patient's consent or a specific court order.
- Anti-discrimination: The updated rules prohibit the use of Part 2 data to discriminate against patients in areas such as employment, housing, and access to services.
- Re-disclosure restrictions: Even after alignment, entities that receive Part 2 data must include re-disclosure notices, though the practical operation of this requirement has been modified to work better within electronic health information exchange systems.

4. Segmentation and Technical Challenges
One practical challenge that arises from Part 2 is the need to segment or tag SUD treatment records within electronic health record systems so that they can be appropriately protected and disclosed only when proper consent is obtained. The Cures Act's push for interoperability has accelerated the development of technical standards to enable this segmentation, but it remains a complex area of implementation.

Key Concepts for the CIPP/US Exam

When studying this topic, focus on the following concepts:

- Scope of 42 CFR Part 2: Know what constitutes a Part 2 program (federally assisted SUD treatment programs) and what types of records are covered (records of the identity, diagnosis, prognosis, or treatment of any patient maintained in connection with SUD treatment).

- Consent requirements: Understand that Part 2 historically required specific, written patient consent for most disclosures, and know how recent reforms have broadened the ability to use a single consent for TPO disclosures.

- Re-disclosure prohibition: This is a distinguishing feature of Part 2 that does not have a direct parallel in HIPAA. Recipients of Part 2 information are bound by the re-disclosure prohibition.

- Exceptions to consent: Be familiar with the limited exceptions (medical emergency, audit/evaluation, QSOAs, court orders, child abuse reporting, research).

- Court order vs. subpoena: A regular subpoena is not sufficient to compel disclosure of Part 2 records. A specific court order following the procedures outlined in Part 2 is required. This is a frequently tested distinction.

- Relationship to HIPAA: Part 2 is more restrictive than HIPAA. When both apply, the more protective standard prevails. However, recent reforms have aligned Part 2 more closely with HIPAA in areas like breach notification and enforcement.

- Information blocking and the privacy exception: Compliance with Part 2 is a valid reason not to share data under the Cures Act's information blocking framework.

- Anti-discrimination protections: Part 2 data cannot be used to discriminate against patients. This is a newer provision reinforced by recent rulemaking.

- Criminal penalties: Know that Part 2 violations can carry criminal fines, and that recent reforms have also extended HIPAA-style civil monetary penalties to Part 2 violations.

Exam Tips: Answering Questions on the 21st Century Cures Act and 42 CFR Part 2

Tip 1: Identify Whether Part 2 Applies
When you encounter a question involving substance use disorder treatment records, immediately ask: Is this a federally assisted program? If yes, 42 CFR Part 2 likely applies. If the question involves general health records without an SUD treatment component, Part 2 may not apply, and HIPAA alone may govern.

Tip 2: Apply the More Restrictive Standard
When both HIPAA and Part 2 apply to the same data, the answer will almost always require compliance with the more restrictive Part 2 standard. If a question asks whether a covered entity can disclose SUD records for treatment purposes without patient consent, remember that under traditional Part 2 rules, consent is required — even though HIPAA would allow disclosure for TPO without individual authorization. Note, however, that recent reforms allow a single general consent for TPO disclosures.

Tip 3: Watch for the Re-disclosure Trap
Questions may test whether a recipient of Part 2 information can further share that information. The answer is generally no — not without additional consent or an applicable exception. The re-disclosure notice is a critical safeguard. If the question involves a downstream entity using SUD data, this is likely the concept being tested.

Tip 4: Distinguish Court Orders from Subpoenas
This is a high-yield distinction for the exam. If a question asks whether a subpoena is sufficient to obtain Part 2 records, the answer is no. A specific court order following Part 2 procedures is required. The court must find good cause, and the standard for obtaining a Part 2 court order is higher than for a typical subpoena.

Tip 5: Remember the Information Blocking Privacy Exception
If a question presents a scenario where a healthcare provider is refusing to share electronic health information that includes SUD treatment records, and asks whether this constitutes information blocking under the Cures Act, the answer is likely no — provided the refusal is based on compliance with 42 CFR Part 2 and the patient has not given consent. The privacy exception protects entities that withhold data to comply with applicable law.

Tip 6: Know the Narrow Exceptions
Be prepared to identify the specific circumstances under which Part 2 records can be disclosed without patient consent. These include medical emergencies (limited to medical personnel), audit and evaluation activities by specified entities, QSOAs, reporting of suspected child abuse or neglect, court orders, and certain approved research activities. If a question presents a scenario not fitting one of these exceptions, consent is required.

Tip 7: Understand the Policy Rationale
Exam questions sometimes test your understanding of why a law exists rather than just its mechanics. The core policy rationale for Part 2 is to encourage individuals to seek SUD treatment without fear that their records will be used against them. If a question asks about the purpose or rationale, this is the key point.

Tip 8: Stay Current on Alignment Changes
The CIPP/US exam may test your knowledge of recent regulatory developments. Be aware that the CARES Act and the Consolidated Appropriations Act of 2023 made significant changes to Part 2, including aligning it more closely with HIPAA for TPO disclosures, applying HIPAA breach notification requirements, and adding anti-discrimination protections. The 2024 final rule from HHS implementing these changes is also relevant.

Tip 9: Use Process of Elimination
When facing a multiple-choice question on this topic, eliminate answers that treat SUD records the same as general health information under HIPAA. Part 2 almost always imposes additional requirements. Also eliminate answers that suggest Part 2 records can be disclosed via subpoena alone or that recipients can freely re-disclose the information.

Tip 10: Look for Keywords
Key terms in exam questions that signal Part 2 applicability include: substance use disorder, alcohol and drug treatment, federally assisted program, re-disclosure, SUD records, and Part 2 program. When you see these terms, immediately apply the Part 2 framework rather than defaulting to general HIPAA rules.

Summary

The 21st Century Cures Act and 42 CFR Part 2 together represent a complex but critically important area of U.S. privacy law. The Cures Act drives interoperability and the free flow of health information, while Part 2 serves as a vital check on that free flow by imposing heightened consent, re-disclosure, and use restrictions on SUD treatment records. For CIPP/US exam purposes, mastering the distinctions between HIPAA and Part 2, understanding the exceptions to Part 2's consent requirement, recognizing the information blocking privacy exception, and grasping the evolving alignment between these frameworks will position you to answer questions on this topic with confidence and accuracy.